ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA, a Switzerland-based biopharmaceutical company, furnished this Form 6-K in November 2022. The filing identifies unaudited IFRS condensed consolidated interim financial statements for the three and nine months ended September 30, 2022.
Financial metrics
The provided filing text contains only the Form 6-K cover page and exhibit index. It does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balances, or other financial metrics.
Material changes versus the prior comparable period
The provided text does not include the financial statements or management’s discussion necessary to assess changes versus the prior-year comparable periods.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risk factors, contingencies, or unusual items are described in the provided text. The filing references Exhibit 99.2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, and Exhibit 99.3, a press release dated November 8, 2022, but their contents are not included.
Key facts for investor verification
- Verify the unaudited IFRS interim financial statements in Exhibit 99.1 for the three and nine months ended September 30, 2022.
- Review Exhibit 99.2 for operating results, liquidity, cash runway, debt, commitments, risks, and management commentary.
- Review Exhibit 99.3 for any earnings-release metrics, pipeline updates, guidance, or other disclosures.
- Note that the filing, including Exhibits 99.1 and 99.2, is incorporated by reference into specified Form F-3 registration statements, while Exhibit 99.3 is excluded from that incorporation by reference.